Literature DB >> 30967367

Acalabrutinib for mantle cell lymphoma.

Thomas E Witzig1, David Inwards1.   

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30967367     DOI： 10.1182/blood.2019852368

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  4 in total

1.  Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience.

Authors:  Antonio Gutierrez; Leyre Bento; Silvana Novelli; Alejandro Martin; Gonzalo Gutierrez; Maria Queralt Salas; Mariana Bastos-Oreiro; Ariadna Perez; Rafael Hernani; Maria Cruz Viguria; Oriana Lopez-Godino; Juan Montoro; Jose Luis Piñana; Christelle Ferra; Rocio Parody; Carmen Martin; Ignacio Español; Lucrecia Yañez; Guillermo Rodriguez; Joud Zanabili; Pilar Herrera; Maria Rosario Varela; Antonia Sampol; Carlos Solano; Dolores Caballero
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

Review 2.  Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy.

Authors:  Miriam Marangon; Carlo Visco; Anna Maria Barbui; Annalisa Chiappella; Alberto Fabbri; Simone Ferrero; Sara Galimberti; Stefano Luminari; Gerardo Musuraca; Alessandro Re; Vittorio Ruggero Zilioli; Marco Ladetto
Journal:  Cancers (Basel)       Date:  2021-01-14       Impact factor: 6.639

3.  Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry.

Authors:  Marie-Kristin Tilch; Carlo Visco; Sandra Kinda; Olivier Hermine; Milena Kohn; Caroline Besson; Sylvain Lamure; Rémy Duléry; Simone Ragaini; Toby A Eyre; Tom Van Meerten; Anke Ohler; Steffen Eckerle; Martin Dreyling; Georg Hess; Eva Giné; Maria Gomes da Silva
Journal:  Hemasphere       Date:  2022-04-08

Review 4.  Management of Drug Resistance in Mantle Cell Lymphoma.

Authors:  Gaël Roué; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.